News

GSK

NIH Launches Multi-Organizational Partnership to Advance Parkinson's Disease Clinical Trials

Edward Kim | Equities.com |

To identify and validate promising biomarkers for Parkinson's disease (Image: NIH)


​Top Picks 2018: Does Glaxo SmithKline Deserve Investors' Patience?

MoneyShow | Equities.com |

Glaxo is hugging the bottom of its recent trading range.


GlaxoSmithKline Gets FDA Approval for First Targeted EGPA Treatment

Edward Kim | Equities.com |

First available targeted treatment for eosinophilic granulomatosis with polyangiitis (Image: ProProfs)


​Here's The Real Importance Of The Latest Novartis AG (ADR) (NYSE:NVS) News

Mark Collins | Equities.com |

Here's what just happened with Novartis and why it's so important.


​Markets May Have Got the Latest Ionis Pharmaceuticals, GlaxoSmithKline News Wrong

Mark Collins | Equities.com |

Here's why the recent decision by GSK to turn down Ionis' TTR drug may not be as bad as it seems.


​Here's Where And Why VBI Vaccines Fits Into the Hepatitis B Picture

Samuel Rae | Equities.com |

The company was just added to the Russell 2000 and Russell 3000 indexes.


​Why Glaxo Has Been Climbing Since the Election

MoneyShow | Equities.com |

GSK broke above $42 last month after releasing strong first quarter financial results.


Three Companies Spearheading a Shift in the Hepatitis B Healthcare Space

Samuel Rae | Equities.com |

A look at the frontrunners in one of the fastest growing spaces in healthcare.


Bill O'Reilly Is Losing Advertisers, but Is He Losing Fans?

CommPRO Global, Inc. | Equities.com |

Tough times for Papa Bear...


How Biotech Investors Can Turn FDA Obstacles Into Profitable Opportunities

The Life Sciences Report | Equities.com |

Being temporarily burned by the U.S. Food and Drug Administration can be a mixed blessing for a biotech with a good product in the pipeline. In an interview with The Life Sciences Report, Chen


Sponsored Financial Content

Market Movers